1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.


Our 199-page report provides 153 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.



Forecasts from 2015-2025 and other analyses show you commercial prospects



Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.



See revenue forecasts for the leading submarkets and indications



How will submarkets perform to 2025? Our study forecasts revenues in the following cholesterol-lowering drugs submarkets and products:

- Statins and Fixed-Dose Combinations

o Crestor

o Lipitor

o Livalo

o Lescol/Lescol XL

o Zocor

o Vytorin

o Caduet

o Other Statins and Fixed-Dose Combinations (grouped forecast)

- Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs

o Zetia

o Welchol

o Tricor

o Other cholesterol-lowering drugs (grouped forecast)

- PCSK9 Inhibitors

o Praluent

o Repatha

o RN316

o Other PCSK9 Inhibitors (grouped forecast)

- Novel Cholesterol-Lowering Drugs

o Juxtapid

o Kynamro

o MK-0859

o Other novel cholesterol-lowering drugs (grouped forecast)



See revenue forecasts for the leading international markets



How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:

- US

- Japan

- Germany

- France

- Italy

- Spain

- UK

- China

- Brazil

- Russia

- India



Leading companies and potential for market growth



Overall revenue for the cholesterol-lowering drugs market will reach $24.63bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. Shifts in diets and lifestyles will contribute to rising levels of high cholesterol, while highly disruptive new treatments will revitalise the market



Our work analyses the key companies in the market. See visiongain’s analysis of 9 leading companies, including these:

- AstraZeneca

- Merck

- Pfizer

- Kowa

- Daiichi Sankyo

- Abbvie

- Novartis

- Sanofi

- Amgen


A company profile gives you the following information where available:

- Discussion of a company’s activities and outlook

- Analysis of products currently on the market as well as pipeline products

- Company news relevant to the market



Discover capabilities, progress, and commercial prospects, helping you stay ahead.



What issues will affect Cholesterol-Lowering Drugs industry?

Our new report discusses issues and events affecting the cholesterol-lowering drugs market. You will find discussions, including qualitative analyses:

- Highly disruptive treatments entering the market

- Increasing potential in both established and emerging markets



You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.



How the Cholesterol-Lowering Drugs Market Forecast 2015-2025 report helps you


In summary, our 199-page report gives you the following knowledge:



- Revenue forecasts to 2025 for the Cholesterol-Lowering Drugs market – discover the industry’s prospects, finding promising places for investments and revenues

- Revenue forecasts to 2025 for submarkets in each – statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs

- Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5 and BRIC

- Assessment of 9 leading companies – analysis of cholesterol-lowering products, revenue, news and upcoming product releases

- Discussion of what stimulates and restrains companies and the market

- Prospects for established firms and those seeking to enter the market

Table Of Contents

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
Table of Contents

1. Report Overview
1.1 Global Cholesterol-Lowering Drugs Market Overview
1.2 Global Cholesterol-Lowering Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Cholesterol-Lowering Drugs
2.1 The Pharmaceutical Industry: A Brief Overview
2.2 Cholesterol: An Essential Lipid
2.3 The Functions of Cholesterol
2.4 Metabolism and Circulation of Cholesterol
2.5 The Role of Cholesterol in Heart Disease
2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy
2.6.1 The IMPROVE-IT Study
2.7 The Role of Cholesterol in Heart Disease: The Controversy
2.8 Raising HDL Cholesterol: A Worthwhile Aim?
2.9 Causes of Hypercholesterolaemia
2.9.1 Atherosclerosis
2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia
2.9.3 Familial Hypercholesterolaemia
2.10 Treatment of Hypercholesterolaemia
2.10.1 UK Treatment Guidelines for Hypercholesterolaemia
2.10.2 US Treatment Guidelines for Hypercholesterolaemia
2.10.3 Lifestyle Changes
2.10.4 Drugs to Lower Cholesterol
2.10.5 Other Therapeutic Approaches
2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment
2.10.5.2 LDL Apheresis: Directly Removing Cholesterol
2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia
2.11 Classification of Cholesterol-Lowering Drugs
2.11.1 Statins
2.11.2 Selective Cholesterol Absorption Inhibitors
2.11.3 Ion Exchange Resins
2.11.4 Fibrates
2.11.5 Other Cholesterol-Lowering Drugs
2.11.6 Novel Cholesterol-Lowering Drugs
2.11.7 PCSK9 Inhibitors
2.12 Phases of Clinical Trials
2.13 Scope of This Report
2.13.1 Products Excluded from This Report
2.14 Currency Exchange Rates in This Report

3. Cholesterol-Lowering Drugs: World Market 2015-2025
3.1 The World Cholesterol-Lowering Drugs Market in 2014
3.1.1 Leading Cholesterol-Lowering Drugs Products
3.1.2 Leading Companies in the Cholesterol-Lowering Drugs Market
3.2 World Cholesterol-Lowering Drugs Market: Sales Forecast 2015-2025
3.3 Cholesterol-Lowering Drugs Market Segments: Sales Forecasts 2015-2025
3.3.1 Cholesterol-Lowering Drugs Market Segmentation
3.4 Changing Market Shares by Segment 2015-2025
3.4.1 World Cholesterol-Lowering Drugs Market: Drivers and Restraints 2015-2025

4. Leading National Markets, 2015-2025
4.1 Regional Breakdown of the World Cholesterol-Lowering Drugs Market
4.1.1 World Cholesterol-Lowering Drugs Market: Regional Forecast 2015-2025
4.1.2 How Will Regional Market Shares Change to 2025?
4.2 National Breakdown of the World Cholesterol-Lowering Drugs Market
4.2.1 World Cholesterol-Lowering Drugs Market: National Markets Forecast 2015-2025
4.2.2 How Will National Market Shares Change to 2025?
4.3 The US Cholesterol-Lowering Drugs Market 2015-2025
4.3.1 US Cholesterol-Lowering Drug Market Forecast 2015-2025
4.3.2 US Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.3.2.1 High Prevalence of High Cholesterol in US
4.4 The Cholesterol-Lowering Drugs Market in the Five Leading European National Markets to 2025
4.4.1 EU5 Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.4.2 The Cholesterol-Lowering Drugs Market in Germany to 2025
4.4.2.1 German Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.3 The Cholesterol-Lowering Drugs Market in France to 2025
4.4.3.1 French Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.4 The Cholesterol-Lowering Drugs Market in the UK to 2025
4.4.4.1 UK Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.5 The Cholesterol-Lowering Drugs Market in Italy to 2025
4.4.5.1 Italian Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.6 The Cholesterol-Lowering Drugs Market in Spain to 2025
4.4.6.1 Spanish Cholesterol-Lowering Drugs Market: Trends and Developments
4.5 The Cholesterol-Lowering Drugs Market in the BRIC National Markets to 2025
4.5.1 BRIC Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.5.2 The Cholesterol-Lowering Drugs Market in China to 2025
4.5.2.1 Chinese Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.2.1.1 Economic Challenges
4.5.2.1.2 Expansion of Healthcare Coverage and Reimbursement
4.5.3 The Cholesterol-Lowering Drugs Market in Brazil to 2025
4.5.3.1 Brazilian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4 The Cholesterol-Lowering Drugs Market in Russia to 2025
4.5.4.1 Russian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4.1.1 Lower Oil Prices
4.5.4.1.2 No Embargo on Foreign Drugs
4.5.5 The Cholesterol-Lowering Drugs Market in India to 2025
4.5.5.1 Indian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.5.1.1 Drug Price Control Order 2014
4.5.5.1.2 Expansion of Healthcare Provision
4.6 The Cholesterol-Lowering Drugs Market in Japan to 2025
4.6.1 Japanese Cholesterol-Lowering Drugs Market: Trends and Developments
4.6.1.1 Generic Penetration to Reach 60% by 2018?
4.6.1.2 Japanese Pharmaceutical Industry Regulatory Reform

5. Statins and Fixed-Dose Combinations: Market and Pipeline 2015-2025
5.1 Statins: Inhibiting HMG-CoA Reductase
5.2 The Statins and Fixed-Dose Combinations Market in 2014
5.3 Statins and Fixed-Dose Combinations: Market Forecast 2015-2025
5.4 How Will Market Shares of Products Change to 2025?
5.5 Crestor (Rosuvastatin, AstraZeneca)
5.5.1 Crestor: Historical Sales Estimate 2009-2014
5.5.2 Crestor: Sales Forecast 2015-2025
5.5.3 Generic Competition for Crestor
5.6 Lipitor (Atorvastatin, Pfizer)
5.6.1 Lipitor: Historical Sales Estimate 2009-2014
5.6.2 Lipitor: Sales Forecast 2015-2025
5.7 Livalo (Pitavastatin, Kowa)
5.7.1 Livalo: Sales Forecast 2015-2025
5.8 Lescol and Lescol XL (Fluvastatin, Novartis)
5.8.1 Lescol/Lescol XL: Sales Forecast 2015-2025
5.9 Zocor (Simvastatin, Merck)
5.9.1 Zocor: Sales Forecast 2015-2025
5.10 Fixed-Dose Combinations
5.11 Vytorin (Simvastatin/Ezetimibe, Merck)
5.11.1 Vytorin: Sales Forecast 2015-2025
5.12 Caduet (Atorvastatin/Amlodipine, Pfizer)
5.12.1 Caduet: Sales Forecast 2015-2025

6. Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market and Pipeline 2015-2025
6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Overview
6.2 The Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market in 2014
6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares of Products Change to 2025?
6.5 Zetia (Ezetimibe, Merck)
6.5.1 The ENHANCE Study: No Additional Benefit
6.5.2 The IMPROVE-IT Study: Reduction in Cardiovascular Risk
6.5.3 Zetia: Sales Forecast 2015-2025
6.6 Welchol (Colesevelam, Daiichi Sankyo)
6.6.1 Threat of Imminent Generic Competition for Welchol
6.6.2 Welchol: Sales Forecast 2015-2025
6.7 Tricor (Fenofibrate, AbbVie)
6.7.1 Generic Erosion of Tricor Sales
6.7.2 Tricor: Sales Forecast 2015-2025

7. PCSK9 Inhibitors: Market and Pipeline 2015-2025
7.1 PCSK9 Inhibitors: The Next Blockbuster Drug Class?
7.2 PCSK9 in Clinical Trials
7.3 PCSK9 Inhibitors and Statins
7.4 PCSK9 Inhibitors: Market Forecast 2015-2025
7.5 How Will Market Shares of Products Change to 2025?
7.6 PCSK9 Inhibitors: Pipeline Analysis 2015-2025
7.7 Praluent (Alirocumab, Sanofi/Regeneron)
7.7.1 Praluent: Sales Forecast 2015-2025
7.8 Repatha (Evolocumab, Amgen)
7.8.1 GAUSS-2
7.8.2 RUTHERFORD-2
7.8.3 LAPLACE-2
7.8.4 Repatha: Sales Forecast 2015-2025
7.9 RN316 (Bococizumab, Pfizer)
7.9.1 RN316: Sales Forecast 2015-2025
7.10 Oral PCSK9 Inhibitor (Pfizer)
7.11 PF-06427878 (Pfizer)
7.12 PCSK9 Vaccine (Pfizer)
7.13 SX-PCK9 (Serometrix)
7.14 Discontinued Pipeline Products
7.14.1 BMS-962476 (Adnectin, Bristol-Myers Squibb)
7.14.2 LY3015014 (Eli Lilly)

8. Novel Cholesterol-Lowering Drugs: Market and Pipeline 2015-2025
8.1 Novel Cholesterol-Lowering Drugs: Overview
8.2 Novel Cholesterol-Lowering Drugs Market in 2014
8.3 Novel Cholesterol-Lowering Drugs: Market Forecast 2015-2025
8.4 How Will Market Shares of Products Change to 2025?
8.5 CETP Inhibitors: Overview
8.5.1 CETP Inhibitors: Pipeline Analysis 2015-2025
8.5.2 MK-0859 (Anacetrapib, Merck)
8.5.2.1 MK-0859 (Anacetrapib): Sales Forecast 2015-2025
8.5.3 Dalcetrapib (DalCor)
8.5.4 DEZ-001/TA-8995 (CETP Inhibitor, Dezima/Amgen)
8.5.5 DRL-17822 (CETP Inhibitor, Dr. Reddy's Laboratories)
8.5.6 PRC-4016 (Icosabutate, ProNova BioPharma)
8.5.7 K-312 (CETP Inhibitor, Kowa)
8.6 MTTP Inhibitors: Market and Pipeline Analysis 2015-2025
8.6.1 Juxtapid (Lomitapide, Aegerion Pharmaceuticals)
8.6.1.1 Juxtapid (Lomitapide): Sales Forecast 2015-2025
8.7 ApoB Inhibitors: Market and Pipeline Analysis 2015-2025
8.7.1 Kynamro (Mipomersen, Isis Pharmaceuticals/Sanofi)
8.7.1.1 Kynamro (Mipomersen): Drug Launch and Pricing Strategy
8.7.1.2 Kynamro (Mipomersen): Sales Forecast 2015-2025
8.8 Other Drug Classes: Market and Pipeline Analysis 2015-2025
8.8.1 K-877 (PPAR-? Agonist, Kowa)
8.8.2 REGN1500 (ANGPTL3 Inhibitor, Regeneron)
8.8.3 ETC-1002 (ACL Inhibitor, Esperion Therapeutics)
8.8.4 ALN-PCS02 and ALN-PCSsc (Alnylam)
8.9 Discontinued Pipeline Products
8.9.1 Torcetrapib
8.9.2 LY2484595 (Evacetrapib)


9. Leading Companies in the Cholesterol-Lowering Drugs Market
9.1 Leading Cholesterol-Lowering Drugs Manufacturers in 2014
9.1.1 Leading Companies: Market Forecast 2015-2025
9.1.2 How Will Leading Companies' Market Shares Change to 2025?
9.2 AstraZeneca
9.2.1 AstraZeneca: Cholesterol-Lowering Drugs
9.2.2 AstraZeneca: Sales Forecast 2015-2025
9.2.3 AstraZeneca: Recent Developments
9.2.3.1 Cholesterol Awareness Initiative in America
9.2.3.2 AstraZeneca Rejects Pfizer Takeover Bid
9.3 Merck
9.3.1 Merck: Cholesterol-Lowering Drugs
9.3.2 Merck: Sales Forecast 2015-2025
9.3.3 Merck: Recent Developments
9.3.3.1 Bayer Acquires Merck's Consumer Health Business
9.3.3.2 Study Shows Lower LDL Levels Are More Beneficial
9.4 Pfizer
9.4.1 Pfizer: Cholesterol-Lowering Drugs
9.4.2 Pfizer: Sales Forecast 2015-2025
9.4.3 Pfizer: Recent Developments
9.4.3.1 Pfizer Ends Over-The-Counter Lipitor Program
9.4.3.2 Development of Oral PCSK9 Inhibitor
9.5 Kowa
9.5.1 Kowa: Cholesterol-Lowering Drugs
9.5.2 Kowa: Sales Forecast 2015-2025
9.5.3 Kowa: Recent Developments
9.5.3.1 Development of K-312
9.5.3.2 Development of K-887
9.6 Daiichi Sankyo
9.6.1 Daiichi Sankyo: Cholesterol-Lowering Drugs
9.6.2 Daiichi Sankyo: Sales Forecast 2015-2025
9.6.3 Daiichi Sankyo: Recent Developments
9.6.3.1 Staff Reduction at US Operation
9.7 AbbVie
9.7.1 AbbVie: Cholesterol-Lowering Drugs
9.7.2 AbbVie: Sales Forecast 2015-2025
9.7.3 AbbVie: Recent Developments
9.7.3.1 Possible Marketing Cost Reductions
9.8 Novartis
9.8.1 Novartis: Cholesterol-Lowering Drugs
9.8.2 Novartis: Sales Forecast 2015-2025
9.9 Sanofi
9.9.1 Sanofi: Cholesterol-Lowering Drugs
9.9.2 Sanofi: Sales Forecast 2015-2025
9.9.3 Sanofi: Recent Developments
9.9.3.1 Purchase of Priority Review Voucher from BioMarin Pharmaceuticals
9.10 Amgen
9.10.1 Amgen: Cholesterol-Lowering Drugs
9.10.2 Amgen: Sales Forecast 2015-2025
9.10.3 Amgen: Recent Developments
9.10.3.1 Amgen Sues Sanofi and Regeneron To Block Praluent

10. Qualitative Analysis of the Cholesterol-Lowering Drugs Market 2015-2025
10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market
10.2 Strengths
10.2.1 Strong Pipeline
10.2.2 High Profile Encouraging Healthcare Provision
10.3 Weaknesses
10.3.1 Increasing Generic Penetration
10.3.2 Approved Indications Limited for New Products
10.4 Opportunities
10.4.1 Increasing Prevalence in Emerging Markets
10.4.2 Possible Additional Indications
10.5 Threats
10.5.1 Patent Expiry
10.5.2 Cost-Containment
10.6 Porter's Five Forces Analysis of the Cholesterol-Lowering Drugs Market
10.6.1 Rivalry among Competitors [High]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Low]
10.6.4 Power of Buyers [Medium]
10.6.5 Threat of Substitutes [High]

11. Conclusions
11.1 The World Cholesterol-Lowering Drugs Market: 2014-2015
11.2 The World Cholesterol-Lowering Drugs Market Forecast: 2014-2025

12. Glossary

List of Tables
Table 1.1 Leading National Cholesterol-Lowering Drugs Market Forecast 2015 ($m, AGR%)
Table 2.1 Clinical Trial Phases
Table 2.2 Currency Exchange Rates, 2014
Table 3.1 Top 10 Cholesterol-Lowering Drugs: Revenue ($m) and Market Share (%), 2014
Table 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Drug Class, 2014-2025
Table 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2014, 2019 and 2025
Table 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2014
Table 4.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Region, 2014-2025
Table 4.3 Market Shares (%) of Leading Cholesterol-Lowering Drugs Market, 2014, 2019 and 2025
Table 4.4 World Cholesterol-Lowering Drugs Market: Revenues ($m), and Market Shares (%) by National Market, 2014
Table 4.5 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
Table 4.6 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014
Table 4.7 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.8 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.9 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.10 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.11 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.12 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.13 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.14 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.15 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.16 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.17 Russian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.18 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.19 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 5.1 Leading Statins and Fixed-Dose Combinations: Revenue ($m) and Market Shares (%), 2014
Table 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%) by Drug, 2014, 2019 and 2025
Table 5.4 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2009-2014
Table 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.6 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2009-2014
Table 5.7 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.8 Kowa: Livalo Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.9 Novartis: Lescol/Lescol XL Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.10 Merck: Zocor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.11 Merck: Vytorin Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.12 Pfizer: Caduet Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.1 Leading Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Revenue ($m) and Market Shares (%), 2014
Table 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025


6. Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market and Pipeline 2015-2025

6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Overview

6.2 The Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market in 2014

6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Forecast 2015-2025

6.4 How Will Market Shares of Products Change to 2025?

6.5 Zetia (Ezetimibe, Merck)

6.5.1 The ENHANCE Study: No Additional Benefit

6.5.2 The IMPROVE-IT Study: Reduction in Cardiovascular Risk

6.5.3 Zetia: Sales Forecast 2015-2025

6.6 Welchol (Colesevelam, Daiichi Sankyo)

6.6.1 Threat of Imminent Generic Competition for Welchol

6.6.2 Welchol: Sales Forecast 2015-2025

6.7 Tricor (Fenofibrate, AbbVie)

6.7.1 Generic Erosion of Tricor Sales

6.7.2 Tricor: Sales Forecast 2015-2025



7. PCSK9 Inhibitors: Market and Pipeline 2015-2025

7.1 PCSK9 Inhibitors: The Next Blockbuster Drug Class?

7.2 PCSK9 in Clinical Trials

7.3 PCSK9 Inhibitors and Statins

7.4 PCSK9 Inhibitors: Market Forecast 2015-2025

7.5 How Will Market Shares of Products Change to 2025?

7.6 PCSK9 Inhibitors: Pipeline Analysis 2015-2025

7.7 Praluent (Alirocumab, Sanofi/Regeneron)

7.7.1 Praluent: Sales Forecast 2015-2025

7.8 Repatha (Evolocumab, Amgen)

7.8.1 GAUSS-2

7.8.2 RUTHERFORD-2

7.8.3 LAPLACE-2

7.8.4 Repatha: Sales Forecast 2015-2025

7.9 RN316 (Bococizumab, Pfizer)

7.9.1 RN316: Sales Forecast 2015-2025

7.10 Oral PCSK9 Inhibitor (Pfizer)

7.11 PF-06427878 (Pfizer)

7.12 PCSK9 Vaccine (Pfizer)

7.13 SX-PCK9 (Serometrix)

7.14 Discontinued Pipeline Products

7.14.1 BMS-962476 (Adnectin, Bristol-Myers Squibb)

7.14.2 LY3015014 (Eli Lilly)



8. Novel Cholesterol-Lowering Drugs: Market and Pipeline 2015-2025

8.1 Novel Cholesterol-Lowering Drugs: Overview

8.2 Novel Cholesterol-Lowering Drugs Market in 2014

8.3 Novel Cholesterol-Lowering Drugs: Market Forecast 2015-2025

8.4 How Will Market Shares of Products Change to 2025?

8.5 CETP Inhibitors: Overview

8.5.1 CETP Inhibitors: Pipeline Analysis 2015-2025

8.5.2 MK-0859 (Anacetrapib, Merck)

8.5.2.1 MK-0859 (Anacetrapib): Sales Forecast 2015-2025

8.5.3 Dalcetrapib (DalCor)

8.5.4 DEZ-001/TA-8995 (CETP Inhibitor, Dezima/Amgen)

8.5.5 DRL-17822 (CETP Inhibitor, Dr. Reddy's Laboratories)

8.5.6 PRC-4016 (Icosabutate, ProNova BioPharma)

8.5.7 K-312 (CETP Inhibitor, Kowa)

8.6 MTTP Inhibitors: Market and Pipeline Analysis 2015-2025

8.6.1 Juxtapid (Lomitapide, Aegerion Pharmaceuticals)

8.6.1.1 Juxtapid (Lomitapide): Sales Forecast 2015-2025

8.7 ApoB Inhibitors: Market and Pipeline Analysis 2015-2025

8.7.1 Kynamro (Mipomersen, Isis Pharmaceuticals/Sanofi)

8.7.1.1 Kynamro (Mipomersen): Drug Launch and Pricing Strategy

8.7.1.2 Kynamro (Mipomersen): Sales Forecast 2015-2025

8.8 Other Drug Classes: Market and Pipeline Analysis 2015-2025

8.8.1 K-877 (PPAR-? Agonist, Kowa)

8.8.2 REGN1500 (ANGPTL3 Inhibitor, Regeneron)

8.8.3 ETC-1002 (ACL Inhibitor, Esperion Therapeutics)

8.8.4 ALN-PCS02 and ALN-PCSsc (Alnylam)

8.9 Discontinued Pipeline Products

8.9.1 Torcetrapib

8.9.2 LY2484595 (Evacetrapib)





9. Leading Companies in the Cholesterol-Lowering Drugs Market

9.1 Leading Cholesterol-Lowering Drugs Manufacturers in 2014

9.1.1 Leading Companies: Market Forecast 2015-2025

9.1.2 How Will Leading Companies' Market Shares Change to 2025?

9.2 AstraZeneca

9.2.1 AstraZeneca: Cholesterol-Lowering Drugs

9.2.2 AstraZeneca: Sales Forecast 2015-2025

9.2.3 AstraZeneca: Recent Developments

9.2.3.1 Cholesterol Awareness Initiative in America

9.2.3.2 AstraZeneca Rejects Pfizer Takeover Bid

9.3 Merck

9.3.1 Merck: Cholesterol-Lowering Drugs

9.3.2 Merck: Sales Forecast 2015-2025

9.3.3 Merck: Recent Developments

9.3.3.1 Bayer Acquires Merck's Consumer Health Business

9.3.3.2 Study Shows Lower LDL Levels Are More Beneficial

9.4 Pfizer

9.4.1 Pfizer: Cholesterol-Lowering Drugs

9.4.2 Pfizer: Sales Forecast 2015-2025

9.4.3 Pfizer: Recent Developments

9.4.3.1 Pfizer Ends Over-The-Counter Lipitor Program

9.4.3.2 Development of Oral PCSK9 Inhibitor

9.5 Kowa

9.5.1 Kowa: Cholesterol-Lowering Drugs

9.5.2 Kowa: Sales Forecast 2015-2025

9.5.3 Kowa: Recent Developments

9.5.3.1 Development of K-312

9.5.3.2 Development of K-887

9.6 Daiichi Sankyo

9.6.1 Daiichi Sankyo: Cholesterol-Lowering Drugs

9.6.2 Daiichi Sankyo: Sales Forecast 2015-2025

9.6.3 Daiichi Sankyo: Recent Developments

9.6.3.1 Staff Reduction at US Operation

9.7 AbbVie

9.7.1 AbbVie: Cholesterol-Lowering Drugs

9.7.2 AbbVie: Sales Forecast 2015-2025

9.7.3 AbbVie: Recent Developments

9.7.3.1 Possible Marketing Cost Reductions

9.8 Novartis

9.8.1 Novartis: Cholesterol-Lowering Drugs

9.8.2 Novartis: Sales Forecast 2015-2025

9.9 Sanofi

9.9.1 Sanofi: Cholesterol-Lowering Drugs

9.9.2 Sanofi: Sales Forecast 2015-2025

9.9.3 Sanofi: Recent Developments

9.9.3.1 Purchase of Priority Review Voucher from BioMarin Pharmaceuticals

9.10 Amgen

9.10.1 Amgen: Cholesterol-Lowering Drugs

9.10.2 Amgen: Sales Forecast 2015-2025

9.10.3 Amgen: Recent Developments

9.10.3.1 Amgen Sues Sanofi and Regeneron To Block Praluent



10. Qualitative Analysis of the Cholesterol-Lowering Drugs Market 2015-2025

10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market

10.2 Strengths

10.2.1 Strong Pipeline

10.2.2 High Profile Encouraging Healthcare Provision

10.3 Weaknesses

10.3.1 Increasing Generic Penetration

10.3.2 Approved Indications Limited for New Products

10.4 Opportunities

10.4.1 Increasing Prevalence in Emerging Markets

10.4.2 Possible Additional Indications

10.5 Threats

10.5.1 Patent Expiry

10.5.2 Cost-Containment

10.6 Porter's Five Forces Analysis of the Cholesterol-Lowering Drugs Market

10.6.1 Rivalry among Competitors [High]

10.6.2 Threat of New Entrants [Medium]

10.6.3 Power of Suppliers [Low]

10.6.4 Power of Buyers [Medium]

10.6.5 Threat of Substitutes [High]



11. Conclusions

11.1 The World Cholesterol-Lowering Drugs Market: 2014-2015

11.2 The World Cholesterol-Lowering Drugs Market Forecast: 2014-2025



12. Glossary



List of Tables

Table 1.1 Leading National Cholesterol-Lowering Drugs Market Forecast 2015 ($m, AGR%)

Table 2.1 Clinical Trial Phases

Table 2.2 Currency Exchange Rates, 2014

Table 3.1 Top 10 Cholesterol-Lowering Drugs: Revenue ($m) and Market Share (%), 2014

Table 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Drug Class, 2014-2025

Table 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2014, 2019 and 2025

Table 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2014

Table 4.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Region, 2014-2025

Table 4.3 Market Shares (%) of Leading Cholesterol-Lowering Drugs Market, 2014, 2019 and 2025

Table 4.4 World Cholesterol-Lowering Drugs Market: Revenues ($m), and Market Shares (%) by National Market, 2014

Table 4.5 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by National Market, 2014-2025

Table 4.6 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014

Table 4.7 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.8 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.9 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.10 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.11 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.12 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.13 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.14 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.15 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.16 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.17 Russian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.18 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 4.19 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025

Table 5.1 Leading Statins and Fixed-Dose Combinations: Revenue ($m) and Market Shares (%), 2014

Table 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025

Table 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%) by Drug, 2014, 2019 and 2025

Table 5.4 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2009-2014

Table 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 5.6 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2009-2014

Table 5.7 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 5.8 Kowa: Livalo Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 5.9 Novartis: Lescol/Lescol XL Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 5.10 Merck: Zocor Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 5.11 Merck: Vytorin Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 5.12 Pfizer: Caduet Revenue ($m), AGR (%) and CAGR (%), 2014-2025

Table 6.1 Leading Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Revenue ($m) and Market Shares (%), 2014

Table 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Probucol (CAS 23288-49-5) Industry Market Report

2016 Probucol (CAS 23288-49-5) Industry Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Probucol Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Probucol industry with a focus on the Chinese market. ...

2016 Global and Chinese Ezetimibe (CAS 163222-33-1) Industry Market Research Report

2016 Global and Chinese Ezetimibe (CAS 163222-33-1) Industry Market Research Report

  • $ 2800
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Ezetimibe (CAS 163222-33-1) Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Ezetimibe (CAS 163222-33-1) industry ...

Global and Chinese Policosanol (CAS 557-61-9) Industry, 2016 Market Research Report

Global and Chinese Policosanol (CAS 557-61-9) Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • November 2016
  • by Prof Research

The 'Global and Chinese Policosanol Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Policosanol industry with a focus on the Chinese ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.